MACROGENICS, INC. Financing Cash Flow
MACROGENICS, INC. (MGNX) reported Financing Cash Flow of $59.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- MACROGENICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $60.17M, a 13.72% decline year-over-year.
- MACROGENICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$207.00K.
- MACROGENICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $57.00K, a 63.23% decline year-over-year.
- MACROGENICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- MACROGENICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $69.51M, a 7141.04% increase from fiscal 2024.
- MACROGENICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $960.00K, a 99.36% decline from fiscal 2023.
- MACROGENICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $150.36M, a 8963.35% increase from fiscal 2022.
- MACROGENICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $1.66M, a 98.65% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $59.97M 10-Q · filed 2026-08-14 | $60.02M derived: sum of 3 quarters · filed 2026-08-14 | $60.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$207.00K 10-Q · filed 2026-05-13 | -$150.00K derived: sum of 2 quarters · filed 2026-05-13 | -$150.00K derived: sum of 3 quarters · filed 2026-05-13 | $69.59M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $57.00K derived: sum of 2 quarters · filed 2026-03-09 | $69.80M derived: sum of 3 quarters · filed 2026-08-14 | $69.51M 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $69.74M derived: sum of 2 quarters · filed 2026-08-14 | $69.46M 10-Q · filed 2025-11-12 | $69.61M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $69.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $69.46M 10-Q · filed 2026-08-14 | $69.61M derived: sum of 3 quarters · filed 2026-08-14 | $69.54M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$282.00K 10-Q · filed 2026-05-13 | -$127.00K derived: sum of 2 quarters · filed 2026-05-13 | -$195.00K derived: sum of 3 quarters · filed 2026-05-13 | $430.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $87.00K derived: sum of 2 quarters · filed 2026-03-09 | $712.00K derived: sum of 3 quarters · filed 2026-03-09 | $960.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | -$68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $557.00K derived: sum of 2 quarters · filed 2025-11-12 | $805.00K 10-Q · filed 2025-11-12 | $1.08M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $625.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $873.00K 10-Q · filed 2025-08-14 | $1.15M derived: sum of 3 quarters · filed 2026-03-09 | $51.06M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $248.00K 10-Q · filed 2025-05-13 | $521.00K derived: sum of 2 quarters · filed 2026-03-09 | $50.43M derived: sum of 3 quarters · filed 2026-03-09 | $50.49M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $50.18M derived: sum of 2 quarters · filed 2026-03-09 | $50.24M derived: sum of 3 quarters · filed 2026-03-09 | $150.36M 10-K · filed 2026-03-09 |
| 2023-09-30 | $49.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $49.97M derived: sum of 2 quarters · filed 2024-11-05 | $150.09M 10-Q · filed 2024-11-05 | $151.45M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $100.18M 10-Q · filed 2024-08-06 | $101.54M derived: sum of 3 quarters · filed 2025-03-20 | $101.54M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-03-31 | $100.12M 10-Q · filed 2024-05-09 | $101.48M derived: sum of 2 quarters · filed 2025-03-20 | $101.48M derived: sum of 3 quarters · filed 2025-03-20 | $101.74M derived: sum of 4 quarters · filed 2025-03-20 |
| 2022-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.36M derived: sum of 2 quarters · filed 2025-03-20 | $1.62M derived: sum of 3 quarters · filed 2025-03-20 | $1.66M 10-K · filed 2025-03-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $263.00K derived: sum of 2 quarters · filed 2023-11-06 | $300.00K 10-Q · filed 2023-11-06 | $1.10M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $300.00K 10-Q · filed 2023-08-09 | $1.10M derived: sum of 3 quarters · filed 2024-03-07 | $20.07M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $37.00K 10-Q · filed 2023-05-09 | $837.00K derived: sum of 2 quarters · filed 2024-03-07 | $19.81M derived: sum of 3 quarters · filed 2024-03-07 | $22.16M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $19.77M derived: sum of 2 quarters · filed 2024-03-07 | $22.12M derived: sum of 3 quarters · filed 2024-03-07 | $122.78M 10-K · filed 2024-03-07 |
| 2021-09-30 | $18.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $21.32M derived: sum of 2 quarters · filed 2022-11-03 | $121.98M 10-Q · filed 2022-11-03 | $123.08M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $103.00M 10-Q · filed 2022-08-08 | $104.11M derived: sum of 3 quarters · filed 2023-03-15 | $178.17M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $100.66M 10-Q · filed 2022-05-03 | $101.76M derived: sum of 2 quarters · filed 2023-03-15 | $175.82M derived: sum of 3 quarters · filed 2023-03-15 | $274.84M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $75.17M derived: sum of 2 quarters · filed 2023-03-15 | $174.18M derived: sum of 3 quarters · filed 2023-03-15 | $174.34M 10-K · filed 2023-03-15 |
| 2020-09-30 | $74.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $173.08M derived: sum of 2 quarters · filed 2021-11-02 | $173.24M 10-Q · filed 2021-11-02 | $173.54M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $99.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $99.18M 10-Q · filed 2021-07-29 | $99.47M derived: sum of 3 quarters · filed 2022-02-24 | $99.51M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $162.00K 10-Q · filed 2021-04-29 | $459.00K derived: sum of 2 quarters · filed 2022-02-24 | $496.00K derived: sum of 3 quarters · filed 2022-02-24 | $1.13M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $334.00K derived: sum of 2 quarters · filed 2022-02-24 | $967.00K derived: sum of 3 quarters · filed 2022-02-24 | $119.97M 10-K · filed 2022-02-24 |
| 2019-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $670.00K derived: sum of 2 quarters · filed 2020-11-04 | $119.67M 10-Q · filed 2020-11-04 | $120.15M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $633.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $119.64M 10-Q · filed 2020-07-31 | $120.11M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $119.00M 10-Q · filed 2020-05-05 | $119.48M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $475.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $104.99M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $104.52M 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $35.35M 10-K · filed 2020-02-25 | |||
| 2013-12-31 | $85.02M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | $85.87M 10-K · filed 2014-03-20 | ||
| 2013-09-30 | $851.18K 10-Q · filed 2013-11-12 | |||
| 2012-12-31 | $2.52K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | $46.83K 10-K · filed 2014-03-20 | ||
| 2012-09-30 | $44.31K 10-Q · filed 2013-11-12 | |||
| 2011-12-31 | $12.09M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |